Translational Biology Laboratory (S-25/26)Â
School of Life Sciences, University of Hyderabad
OUR GOAL
Roy's Lab is dedicated to cultivating a liberating atmosphere for scientific exploration, fostering a free spirit within its walls. We wholeheartedly invest in the growth and development of students, postdocs, and research technicians, nurturing their aspirations and empowering them to achieve their goals. With an open-minded approach, we actively encourage discussions and welcome collaborations, recognizing their potential to enrich our scientific pursuits. Grounded in the principles of honesty and ethical values, we steadfastly adhere to the pursuit of science, creating a virtuous cycle that drives our lab's progress.
Dr. Roy Karnati is an Associate Professor in the Department of Animal Biology at the University of Hyderabad (UoH). He has more than 15 years of research and industrial experience in life sciences. During his PhD at the University of Hyderabad, Dr. Roy was supported by a CSIR fellowship to understand cyclooxygenase-2 and reactive oxygen species-mediated regulation of MDR1 expression in HepG2 and RAW 264.7 cells. He then moved to the University of Virginia (USA) for postdoctoral research. Dr. Roy now runs a Translational & Tumor Biology Lab at UoH. The overarching goal of his research group is to understand the molecular mechanisms of infection and inflammation conditions in dry eye diseases and cancer, with a specific focus on metabolism, regulation, and the design and screening of inhibitors. His lab has experience handling various cell culture lines, animal model experiments, in-vitro enzyme activity assays, ChIP, protein expression and purification studies, stable cell line generation and metabolic profiling.
 Education/Training
Postdoctoral Research Associate – University of Virginia, USA
DST PURSE Fellow – University of Hyderabad
SERB Young Scientist – University of Hyderabad
Research Consultant and Principal Scientist – GeneSys Biologics, Hyderabad
Adhoc Faculty – NIT Warangal
Manager – FABA Hyderabad
Ph.D. – University of Hyderabad
 Awards and Recognitions
SERB-Young Scientist 2012
DST-PURSE fellowship 2010
Research exchange visitor, University of Virginia (2007-2009)
Project work published as cover page, Asia Pacific Centre for Transfer of Technology, UN
Junior Research Fellow, Council of Scientific and Industrial Research (CSIR)
Senior Research Fellow, Council of Scientific and Industrial Research (CSIR)
Lectureship by UGC
Merit Scholarship from the Department of Biotechnology 2000-2002
NEWS & LATEST UPDATES
Mr Ravi Ranjan successfully defended his PrePhD on 8th December 2025
Mr Mayank Bajaj was invited to present at Molecular Analysis of Precison (MAP) Oncology Conference at Paris, France
Mr Jitesh Gupta successfully defended his PrePhD on 15th April 2025
Mr Mayank Bajaj received oral presentation cash award at Drug Discovery and Development WorkshopÂ
Mr Jitesh Gupta was invited to present at EMBL Protein Synthesis and Translational Control Medicine Conference at Heidelberg Germany Â
Mr Jitesh Gupta got selected for ASWAR award 2021 for best popular science stories under PhD category
RECENT PUBLICATIONS
Integrative machine learning-guided in silico and in vitro approach reveals selective small molecule inhibitors targeting mutant IDH1
Mayank Bajaj, a  Rohit Kumar, b  Vishal Pandey,b  Sahanawaz Parvez,b  Hemanth Kumar Tanneru,c  Polamarasetty Aparoy*b and Roy Karnati *a Â
Brief Summary:Â
We know gene mutations drive cancer. But identifying the right drug to stop them? That requires screening millions of compounds.Â
Here, our teamÂ
✅ Built a robust Machine Learning (Random Forest) model to screen compound libraries and identify key hotspots driving Brain Cancer (Gliomas) mediated by IDH1 gene.Â
✅ We identified 5 promising FDA-approved candidates capable of repurposing against that faulty MT-IDH1.
✅ We validated that these compounds selectively inhibit the mutant cancer-driving enzyme while sparing the healthy wild-type enzyme.
Exosomes: Insights from Retinoblastoma and Other Eye Cancers
Kashmiri Lande1, Jitesh Gupta1, Ravi Ranjan1, Manjari Kiran2, Luis Fernando Torres Solis3, Arturo SolÃs Herrera4, Gjumrakch Aliev5,6,7,8,* and Roy Karnati1,**a Â
Brief Summary:Â
This work reviews the pathophysiological role of exosomes in the ocular environment, emphasising their utility in the management of Retinoblastoma (RB). It evaluates exosomal cargo as a source for novel, non-invasive diagnostic and therapeutic targets.Â
Here, our team
✅ Exosomes in fluids like tears and vitreous humour are critical mediators of cell-to-cell communication and disease propagation in ocular malignancies.
✅The study advocates for exosome-based 'liquid biopsies' to replace high-risk invasive diagnostics, offering a safer method to monitor tumour progression and metastasis.
✅ Integrated analysis reveals that hsa-miR-494 and hsa-miR-9 regulate a common set of 23 proteins within RB tumour exosomes, highlighting key pathways for therapeutic intervention.
FUNDING
ICMR
UoH-IOE
ANRF
CSIR
UGC
DST-SERB
DBT